John Libbey Eurotext

Médecine de la Reproduction

MENU

L’importance du myo-inositol et du D-chiro-inositol pour soutenir la fertilité et la reproduction Volume 23, numéro 3, Juillet-Août-Septembre 2021

Auteurs
Vittorio Unfer for EGOI* (The Experts Group on Inositol in Basic, Clinical Research)a 2 5
1 Mother-Infant Department, University of Modena and Reggio Emilia, Modena, Italy
2 The Experts Group on Inositol in Basic and Clinical Research (EGOI)
3 Faculty of Medicine, University of Lille, Lille, France
4 University of Lyon, Inserm U1060, CarMeN, INSA de Lyon, Université Claude Bernard Lyon 1, Villeurbanne, France
5 Systems Biology Group Lab, Rome, Italy
* Correspondence
a The Experts Group on Inositol in Basic and Clinical Research (EGOI): Vittorio Unfer, Systems Biology Group Lab, Rome, Italy; Fabio Facchinetti, Mother-Infant Department, University of Modena and Reggio Emilia, Modena, Italy/Department of Obstetrics and Gynecology and Pediatrics, University of Modena and Reggio Emilia, Modena, Italy; Appetecchia Marialuisa, Oncological Endocrinology Unit, Regina Elena National Cancer Institute, IRCCS, Rome, Italy; Aragona Cesare, Systems Biology Group Lab, Rome, Italy; Barbaro Daniele, Director of U.O. Endocrinology in Livorno Hospital, USL Nordovest Toscana Italy. Professor at contract University of Pisa; Benvenga Salvatore, Department of Clinical and Experimental Medicine, University of Messina, Italy; Bevilacqua Arturo, Department of Dynamic and Clinical Psychology, Sapienza University, Rome, Italy; Bezerra EspinolaMaria Salomé, Systems Biology Group Lab, Rome, Italy; Bizzarri Mariano, Department of Experimental Medicine, Systems Biology Group, University La Sapienza, Rome, Italy; Systems Biology Group Lab, Rome, Italy; Cantelmi Tonino, Institute for Interpersonal Cognitive Therapy, Rome, Italy; Cavalli Pietro, Humanitas Research Hospital, Rozzano, Milan, Italy; Chan Shiao-Yng, Department of Obstetrics and Ginecology, Yong Loo Lin School of Medicine, National University of Singapore, Malaysia; Chiu Tony Tak Yu, IVF Centre, Hong Kong, China; Copp Andrew J., Newlife Birth Defects Research Centre and Developmental Biology and Cancer Programme, Institute of Child Health, University College London, London, UK; D’Anna Rosario, Department of Human Pathology, University of Messina, Messina, Italy; Dewailly Didier, Faculty of Medicine, University of Lille, Lille, France; Di Lorenzo Cherubino, Researcher at Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome Polo Pontino, Latina, Italy; Diamanti-Kandarakis Evanthia, Department of Endocrinology and Diabetes, HYGEIA Hospital, Marousi, Athens, Greece; Dinicola Simona, Systems Biology Group Lab, Rome, Italy; Greene Nicholas D., Newlife Birth Defects Research Centre and Developmental Biology and Cancer Programme, Institute of Child Health, University College London, London, UK; Hernández Marín Imelda, Human Reproduction Department, Hospital Juárez de México, and Universidad Nacional Autónoma de México (UNAM), México City, México; Hod Moshe, Department of Obstetrics and Gynecology Sackler Faculty of Medicine, Tel-Aviv University, Israel; MOR Comprehensive Women's Health Center, Tel-Aviv, Israel; Kamenov Zdravko, Department of Internal Medicine, Medical University of Sofia, Sofia, Bulgaria; Kandaraki Eleni A., Department of Endocrinology and Diabetes, HYGEIA Hospital, Marousi, Athens, Greece; Laganà Antonio Simone, Department of Obstetrics and Gynecology, ‘Filippo Del Ponte’ Hospital, University of Insubria, Varese, Italy; Monastra Giovanni, Systems Biology Group Lab, Rome, Italy; Montanino Oliva Mario, Department of Obstetrics and Gynecology, Santo Spirito Hospital, Rome, Italy; Nestler John E., Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA; Nordio Maurizio, A.S.L. RMF, Civitavecchia (RM), Italy; Özay Ali Cenk, Near East University, Faculty of Medicine, Department of Obstetrics and Gynecology, and Research Center of Experimental Health Sciences, Nicosia, Cyprus; Papalou Olga, Department of Endocrinology and Diabetes, HYGEIA Hospital, Marousi, Athens, Greece; Pkhaladze Lali, Zhordania and Khomasuridze Institute of Reproductology, Tbilisi, Georgia; Porcaro Giuseppina, Women's Health Centre, USL UMBRIA 2, Terni, Italy; Prapas Nikos, Third Department of OB-GYNAE, Aristotle University of Thessaloniki, and IVF Laboratory, IAKENTRO Fertility Centre, Thessaloniki, Greece; Roseff Scott J., Reproductive Endocrinology and Infertility, South Florida Institute for Reproductive Medicine (IVFMD), Florida, USA; Soulage Christophe O., University of Lyon, INSERM U1060, CarMeN, INSA de Lyon, Université Claude Bernard Lyon 1, Villeurbanne, France; Stringaro Annarita, National Center for Drug Research and Evaluation, Italian National Institute of Health, Rome, Italy; Vazquez-Levin Mónica Hebe, National Council of Scientific and Technical Research, Instituto de Biología y Medicina Experimental (IBYME), Buenos Aires, Argentina; Vucenik Ivana, Department of Medical & Research Technology and Pathology, University of Maryland School of Medicine in Baltimore, MD, USA; Wdowiak Artur, Diagnostic Techniques Unit, Medical University of Lublin, Poland

Cette revue détaille les rôles physiologiques de deux sensibilisateurs à l’insuline, le myo-inositol (MI) et le D-chiro-inositol (DCI). Dans l’ovaire humain, le MI est un second messager de l’hormone folliculostimulante (FSH) et le DCI est un inhibiteur de l’aromatase. Ces activités permettent de définir un traitement du syndrome des ovaires polykystiques (SOPK) basé sur l’administration combinée de MI et de DCI, où le meilleur rapport MI:DCI est de 40:1. En outre, le MI joue un rôle essentiel dans la physiologie de la reproduction et a des effets bénéfiques sur le développement des ovocytes, des spermatozoïdes et des embryons. En revanche, le DCI a peu d’effet sur les spermatozoïdes, mais des concentrations élevées dans l’ovaire peuvent avoir un effet négatif sur la qualité des ovocytes et du blastocyste. Dans l’ensemble, les données de la littérature confirment les effets bénéfiques du MI dans la reproduction féminine et masculine, ce qui justifie l’utilisation clinique du MI dans l’assistance médicale à la procréation.